NasdaqCM:SINT

Stock Analysis Report

Executive Summary

Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America.

Rewards

Revenue is forecast to grow 84.06% per year

Earnings have grown 16.4% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($532K)

Does not have a meaningful market cap ($4M)

+ 2 more risks


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Medtronic

NYSE:MDT

Share Price & News

How has Sintx Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SINT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

7.3%

SINT

-0.4%

US Medical Equipment

-1.3%

US Market


1 Year Return

-73.1%

SINT

27.3%

US Medical Equipment

22.0%

US Market

Return vs Industry: SINT underperformed the US Medical Equipment industry which returned 28.4% over the past year.

Return vs Market: SINT underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

SINTIndustryMarket
7 Day7.3%-0.4%-1.3%
30 Day14.1%2.8%1.8%
90 Day-29.5%11.8%9.3%
1 Year-73.1%-73.1%28.3%27.3%24.6%22.0%
3 Year-98.9%-98.9%91.8%86.3%49.2%39.6%
5 Year-100.0%-100.0%131.2%106.5%77.9%58.3%

Price Volatility Vs. Market

How volatile is Sintx Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sintx Technologies undervalued compared to its fair value and its price relative to the market?

0.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SINT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SINT is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SINT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SINT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SINT is good value based on its PB Ratio (0.7x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Sintx Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

9.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SINT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SINT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SINT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SINT's revenue (84.1% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: SINT's revenue (84.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SINT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sintx Technologies performed over the past 5 years?

16.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SINT is currently unprofitable.

Growing Profit Margin: SINT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SINT is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare SINT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SINT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31%).


Return on Equity

High ROE: SINT has a negative Return on Equity (-80.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Sintx Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: SINT's short term assets ($4.9M) exceed its short term liabilities ($2.1M).

Long Term Liabilities: SINT's short term assets ($4.9M) exceed its long term liabilities ($2.5M).


Debt to Equity History and Analysis

Debt Level: SINT's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: SINT's debt to equity ratio has reduced from 190.7% to 0.3% over the past 5 years.


Balance Sheet

Inventory Level: SINT has a high level of physical assets or inventory.

Debt Coverage by Assets: SINT's debt is covered by short term assets (assets are 231.7x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SINT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SINT has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.5% each year.


Next Steps

Dividend

What is Sintx Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SINT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SINT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SINT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SINT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SINT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sintx Technologies's salary, the management and board of directors tenure and is there insider trading?

4.7yrs

Average management tenure


CEO

B. Bal (57yo)

5.3yrs

Tenure

US$401,231

Compensation

Dr. B. Sonny Bal, M.D., J.D., MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since Augu ...


CEO Compensation Analysis

Compensation vs Market: B.'s total compensation ($USD401.23K) is about average for companies of similar size in the US market ($USD519.76K).

Compensation vs Earnings: B.'s compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.7yrs

Average Tenure

57yo

Average Age

Experienced Management: SINT's management team is considered experienced (4.7 years average tenure).


Board Age and Tenure

5.4yrs

Average Tenure

59.5yo

Average Age

Experienced Board: SINT's board of directors are considered experienced (5.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 442.5%.


Management Team

  • Bryan McEntire (67yo)

    Chief Scientific Officer

    • Tenure: 2yrs
    • Compensation: US$249.31k
  • B. Bal (57yo)

    Chairman

    • Tenure: 5.3yrs
    • Compensation: US$401.23k
  • David O'brien (54yo)

    Chief Operating Officer

    • Tenure: 4.7yrs

Board Members

  • Dave Truetzel (62yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$122.00k
  • Eric Stookey (49yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$42.00k
  • B. Bal (57yo)

    Chairman

    • Tenure: 5.3yrs
    • Compensation: US$401.23k
  • Jeff White (65yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$42.00k
  • Giuseppe Pezzotti

    Member of Scientific Advisory Board

    • Tenure: 4.3yrs

Company Information

Sintx Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sintx Technologies, Inc.
  • Ticker: SINT
  • Exchange: NasdaqCM
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.333m
  • Shares outstanding: 2.43m
  • Website: https://www.sintx.com

Number of Employees


Location

  • Sintx Technologies, Inc.
  • 1885 West 2100 South
  • Salt Lake City
  • Utah
  • 84119
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SINTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2014
111NDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. Sintx Technologies, Inc. has a collaboration agreement with CTL Amedica to design and launch spinal implants. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/25 00:31
End of Day Share Price2020/01/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.